Cargando…

A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells

Bispecific T cell engager (BiTE) antibody constructs are successfully used as cancer therapeutics. We hypothesized that this treatment strategy could also be applicable for therapy of human cytomegalovirus (HCMV) infection, since HCMV-encoded proteins are abundantly expressed on the surface of infec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brey, Charlotte U., Proff, Julia, Teufert, Natascha, Salzer, Benjamin, Brozy, Johannes, Münz, Markus, Pendzialek, Jochen, Ensser, Armin, Holter, Wolfgang, Lehner, Manfred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261951/ https://www.ncbi.nlm.nih.gov/pubmed/30487534 http://dx.doi.org/10.1038/s41598-018-36055-2

Ejemplares similares

Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2–CH3 IgG spacer domains
por: Proff, Julia, et al.
Publicado: (2018)

Cytomegalovirus-Infected Cells Resist T Cell Mediated Killing in an HLA-Recognition Independent Manner
por: Proff, Julia, et al.
Publicado: (2016)

Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia
por: Subklewe, Marion, et al.
Publicado: (2014)

Bispecific T cell engager (BiTE(®)) antibody constructs can mediate bystander tumor cell killing
por: Ross, Sandra L., et al.
Publicado: (2017)

Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy
por: Yang, Xiao-mei, et al.
Publicado: (2023)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
por: Kujawski, Maciej, et al.
Publicado: (2019)

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
por: Wu, Jingjing, et al.
Publicado: (2015)

Redirecting T Cells to Ewing's Sarcoma Family of Tumors by a Chimeric NKG2D Receptor Expressed by Lentiviral Transduction or mRNA Transfection
por: Lehner, Manfred, et al.
Publicado: (2012)

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)
por: Stone, Jennifer D., et al.
Publicado: (2012)

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
por: Jitschin, Regina, et al.
Publicado: (2018)

Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
por: Wathikthinnakon, Methi, et al.
Publicado: (2022)

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
por: Ferrari, Francesca, et al.
Publicado: (2015)

Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity
por: Perotti, Michela, et al.
Publicado: (2020)

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
por: Osada, T, et al.
Publicado: (2010)

Characterization of Magnetron Sputtered BiTe-Based Thermoelectric Thin Films
por: Zhang, Zhenxue, et al.
Publicado: (2023)

Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination
por: Li, Fengsheng, et al.
Publicado: (2017)

Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation
por: Baraniak, Ilona, et al.
Publicado: (2019)

1113 Safety and Efficacy of a Cytomegalovirus Glycoprotein B (gB) Vaccine in Adolescent Girls
por: Bernstein, David I., et al.
Publicado: (2014)

A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model
por: Meckler, Joshua F., et al.
Publicado: (2023)

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
por: Kebenko, Maxim, et al.
Publicado: (2018)

T-cell responses against CD19(+) pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
por: Feucht, Judith, et al.
Publicado: (2016)

Re-Analysis of the Widely Used Recombinant Murine Cytomegalovirus MCMV-m157luc Derived from the Bacmid pSM3fr Confirms Its Hybrid Nature
por: Cordsmeier, Arne, et al.
Publicado: (2023)

Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4(+) CTL
por: Hegde, Nagendra R., et al.
Publicado: (2005)

Little role of anti-gB antibodies in neutralizing activity of patient's sera with human cytomegalovirus (HCMV) infection.
por: Park, J. W., et al.
Publicado: (2000)

BiTE secretion from in situ-programmed myeloid cells results in tumor-retained pharmacology
por: Hao, S., et al.
Publicado: (2022)

Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
por: Kegyes, David, et al.
Publicado: (2022)

BiTE‐Secreting CAR‐γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors
por: Huang, Shi‐Wei, et al.
Publicado: (2023)

A Preclinical Embryonic Zebrafish Xenograft Model to Investigate CAR T Cells in Vivo
por: Pascoal, Susana, et al.
Publicado: (2020)

Human Cytomegalovirus gH/gL Forms a Stable Complex with the Fusion Protein gB in Virions
por: Vanarsdall, Adam L., et al.
Publicado: (2016)

Antibody Titers Against Human Cytomegalovirus gM/gN and gB Among Pregnant Women and Their Infants
por: Talavera-Barber, Maria, et al.
Publicado: (2022)

UV-B promotes flavonoid biosynthesis in Ginkgo biloba by inducing the GbHY5-GbMYB1-GbFLS module
por: Liu, Sian, et al.
Publicado: (2023)

Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma
por: Li, Gaowei, et al.
Publicado: (2021)

CAR-T cells and BiTEs in solid tumors: challenges and perspectives
por: Edeline, Julien, et al.
Publicado: (2021)

Different functional states of fusion protein gB revealed on human cytomegalovirus by cryo electron tomography with Volta phase plate
por: Si, Zhu, et al.
Publicado: (2018)

Adult and Cord Blood-Derived High-Affinity gB-CAR-T Cells Effectively React Against Human Cytomegalovirus Infections
por: Olbrich, Henning, et al.
Publicado: (2020)

The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread
por: Gomes, A. C., et al.
Publicado: (2023)

Genome Sequence of the Alcelaphine Gammaherpesvirus 1 Attenuated Laboratory Strain WC11
por: Ensser, Armin
Publicado: (2017)

Vector-based antiviral therapy
por: Ensser, Armin
Publicado: (2006)

Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas
por: Arnone, Claudia Manuela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_441bkv3q1ib1e7tnvmmf29krp4